Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mitazalimab (ADC-1013; JNJ-64457107) is an FcγR-dependent CD40 agonist that exhibits directed activity against tumors. By activating antigen-presenting cells, such as dendritic cells (DC), it triggers the initiation of tumor-reactive T cells. Consequently, Mitazalimab promotes the infiltration and destruction of tumors by tumor-specific T cells and remodels the tumor-infiltrating myeloid microenvironment [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Mitazalimab (ADC-1013; JNJ-64457107) is an FcγR-dependent CD40 agonist that exhibits directed activity against tumors. By activating antigen-presenting cells, such as dendritic cells (DC), it triggers the initiation of tumor-reactive T cells. Consequently, Mitazalimab promotes the infiltration and destruction of tumors by tumor-specific T cells and remodels the tumor-infiltrating myeloid microenvironment [1] [2]. |
Molecular Weight | N/A |
CAS No. | 2055640-86-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mitazalimab 2055640-86-1 inhibitor inhibit